58 results about "Immune reactivity" patented technology

A medicament characterized by comprising an antibody or a fragment thereof having an immunological reactivity with CAPRIN-1 protein, and a topoisomerase I inhibitor together or separately in combination is useful as a medicament for treatment and / or prevention of cancer.

The present disclosure provides compositions and methods for mRNA therapy with reduced immune reactogenicity.

The invention belongs to the field of biological medicines, and particularly relates to an optimized antigen peptide aiming at L858R point mutation of an EGFR exon 21 region and application of the optimized antigen peptide. Compared with a mutant peptide, the optimized antigen peptide has stronger immune cross reaction, can improve the immunoreactivity or curative effect of related tumor vaccines, and can effectively cover more patient crowds.

The application discloses a two-dimensional magnetophoresis separation and detection method and system based on weight distribution, and belongs to the field of biochemical analysis. Based on the designed microfluidic chip, the physical property difference between the non-magnetic material and the magnetic material is utilized, the motion difference thereof in the magnetic field is taken as the distinguishing feature, deep-level signal exploration and analysis based on microbead quantification are realized, the number of the compound after the immune reaction and the motion difference in the magnetic field environment are utilized, force analysis calculation and physical field simulation are carried out, different weights are given to the classified signal probes, the signal strength is more accurately revealed, the two-dimensional magnetophoresis analysis method is combined, and the sensitivity and resolution capability of the analysis are effectively enhanced. In addition, the reaction time of the method is short, the operation steps are few, the multiple modes are optional, the scene applicability is strong, and the circulation use can be realized.

The invention relates to a mesenchymal stem cell immunomodulatory function enhancing technology based on gene editing. The invention relates to the field of biomedical engineering and regenerative medicine, and particularly provides a method for enhancing the immune regulation function of mesenchymal stem cells through a CRISPR-Cas9 gene editing technology, and aims at up-regulating IDO1, IL-10 and other key genes in a targeted manner and remarkably improving the excessive immune response inhibition capability of MSCs. The technology can be used for developing high-efficiency and low-toxicity novel cell drugs for treating autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus.

The invention relates to a micro-fluidic chip and an immunoassay instrument. A micro-fluidic cavity is formed in a body; the microfluidic chamber comprises a first valve control structure, a second valve control structure, a third valve control structure, a fourth valve control structure, a first liquid cavity, a second liquid cavity, a first reaction cavity, a detection reaction cavity and a waste liquid cavity; the first liquid cavity, the first valve control structure, the first reaction cavity, the fourth valve control structure and the waste liquid cavity are communicated in sequence according to the distance from the rotating center from near to far, and the second liquid cavity, the second valve control structure, the detection reaction cavity, the third valve control structure and the waste liquid cavity are communicated in sequence. By designing a first liquid cavity, a second liquid cavity, a first reaction cavity and a detection reaction cavity which are matched with each other, the microfluidic chip is suitable for a delay one-step method and two-step method detection scheme of two-time reaction needing accurate quantification, so that the microfluidic chip can be matched with delay one-step method and two-step method immunoreactions; and the universality of the micro-fluidic chip, especially a disc-type micro-fluidic chip, is further expanded.

The invention discloses an immunodetection system and method based on a digital micro-fluidic chip, the system comprises a micro-fluidic chip, a heating unit, a magnetic field loading unit, a fluorescence detection unit and a control unit, the micro-fluidic chip comprises a liquid injection area, a magnetic mixing area, a magnetic separation area, a detection area, a waste liquid area and an electrode array; the electrode array covers each area and drives liquid drops in the areas to move; the control unit is used for controlling the electrode array to drive the movement sequence and position of the liquid drops in each region according to an immunodetection process; wherein the heating unit is used for regulating and controlling the immune reaction temperature of liquid drops in the magnetic mixing area, and driving the liquid drops to continuously move in the magnetic mixing area through the electrode array covered by the magnetic mixing area, so that samples, magnetic beads and fluorescent microspheres in the liquid drops are fully mixed and react. The immunoreaction time is greatly shortened, the magnetic mixing uniformity is greatly improved, and the immunodetection efficiency and accuracy are improved.

The invention belongs to the technical field of 3D biological printing, and particularly relates to bladder acellular matrix hydrogel, a 3D biological printing bladder patch and a preparation method and application of the bladder acellular matrix hydrogel and the 3D biological printing bladder patch. The bladder acellular matrix hydrogel is prepared from a methacrylated bladder acellular matrix and a photoinitiator. The bladder acellular matrix is firstly subjected to methacrylation, so that the bladder acellular matrix has the photo-crosslinking gelling characteristic, the rheological property of the bladder acellular matrix hydrogel can be improved, the mechanical stability of the bladder acellular matrix hydrogel can be enhanced, and meanwhile, the bladder acellular matrix hydrogel has the environmental characteristic of simulating a bladder tissue extracellular matrix and does not cause immune response. Bio-ink prepared from the bladder acellular matrix hydrogel has the characteristics of shear thinning and temperature response capability, and bladder tissue engineering patches can be printed by using a 3D bio-printer.

Provided is a biosynthesis-based preparation method for a structural material of the human body. A polypeptide of the present application contains the structure of a C-terminal region of (repeating unit)n or (repeating unit)n-; the repeating unit contains an amino acid sequence as shown in SEQ ID NO. 1. Recombinant type V humanized collagen prepared in the present application has high activity in promoting cell adhesion, and does not cause an immune response when applied to the human body; moreover, the preparation method is novel, allows for large-scale production of the recombinant type V humanized collagen, and is widely used in the preparation of structural materials of the human body. The application field includes preparation of high-end medical devices, such as biological dressings, human body biomimetic materials, plastic-beauty materials, organoid culture, cardiovascular stents, coatings, tissue injection filling, ophthalmic materials, gynecological biomaterials, nerve repair and regeneration, liver tissue and vessel repair and regeneration, and 3D printing of artificial organ biomaterials.

The present invention relates to an in vitro method for preparing an immunoreactive agent against human cancer cells infected with an HPV16-associated virus, said method comprising expressing at least part of a nucleic acid sequence encoding an immunoreactive agent obtained from an immune cell stimulated by a complex comprising a human leukocyte antigen (HLA) and a stimulating peptide (stimulating complex), wherein the stimulating peptide (i) consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 1 and SEQ ID NO: 2, and the HLA is from an HLA supertype HLA-A01; (ii) consists of an amino acid sequence of SEQ ID NO: 11, and the HLA is from an HLA supertype HLA-A02; (iii) consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 34 to SEQ ID NO: 37, and the HLA is from an HLA supertype HLA-A03 / A11; (iv) consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 60 and SEQ ID NO: 61, and the HLA is from an HLA supertype HLA-A24; (v) consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 61, SEQ ID NO: 76 and SEQ ID NO: 77, and the HLA is from an HLA supertype HLA-B07; or (vi) consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 61 and SEQ ID NO: 85 to SEQ ID NO: 92, and the HLA is from an HLA supertype HLA-B15; and wherein HPV16-derived peptides consisting of the same amino acid sequence as the stimulating peptides have been demonstrated to be presented by human HPV16-positive cancer cells, and methods and uses related thereto.

The invention relates to a hybridoma cell strain secreting a rofecoxib monoclonal antibody and application of the hybridoma cell strain, and belongs to the technical field of immunodetection. According to the invention, a hybridoma cell strain secreting the rofecoxib monoclonal antibody is obtained through screening by preparing a rofecoxib complete antigen and carrying out animal immune reaction and cell fusion steps, the hybridoma cell strain is preserved in China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC NO.46734. The monoclonal antibody secreted by the hybridoma cell strain has good sensitivity and specificity, the IC50 value to rofecoxib is 20.0 ng / mL, the cross reaction rate to various rofecoxib functional analogues is smaller than 1%, the monoclonal antibody can be applied to preparation of rofecoxib detection products, and an efficient detection method and means are provided for detection of rofecoxib residues in food.

The present invention provides a polymer braided heart valve and a preparation method thereof. The polymer braided heart valve is formed by a braiding process, including an upper fabric layer with a corrugated structure, a flat lower fabric layer and an expanded polytetrafluoroethylene yarn in the middle. The upper fabric layer and the lower fabric layer are fabrics woven from core-shell composite yarns; the core layer of the core-shell composite yarn is a high-elasticity, high-strength core wire, and the outer layer is a polytetrafluoroethylene filament. The present invention coats the polytetrafluoroethylene filament on the surface of the high-elasticity, high-strength core wire, and obtains a core-shell composite yarn for constructing a polymer braided valve by regulating the filament and spinning process parameters, and cooperates with the braiding process to obtain a polymer braided heart valve with upper and lower layers of core-shell composite yarn fabric layers and an expanded polytetrafluoroethylene yarn in the middle; the valve has good structural stability, high strength, elasticity, biocompatibility, and excellent anti-fouling ability, anti-coagulation ability, and the function of reducing immune response, and has good application prospects.

Disclosed herein are methods and kits for assessing the risk of preterm birth (PTB) and hypertensive disorders of pregnancy (HDPs) by analyzing immune responsiveness in a subject.

The invention provides a linear epitope of an African swine fever virus CP312R protein. The amino acid sequence of the linear epitope is SEQ ID NO: 1 or SEQ ID NO: 2. The antigen epitope polypeptide provided by the invention has good antigen specificity and immunoreactivity. The polypeptide can be efficiently combined with an African swine fever virus specific antibody, background interference is low, cross reaction is small, and detection sensitivity and accuracy are remarkably improved. By using the polypeptide as a coating antigen in immunodetection methods such as ELISA or colloidal gold immunochromatography, rapid and accurate detection of ASFV infection can be realized, and the detection result is stable and reliable. Compared with a traditional whole virus antigen or a crude extract antigen, the epitope polypeptide has the advantages of being simple and convenient to prepare, small in batch difference, high in safety and the like, and is suitable for ASFV serological monitoring and diagnosis application.

The present invention relates to a methionine sulfoxide reductase B1 inhibitor and an anticancer composition comprising same. More specifically, the present invention relates to 4-[3-(4-ethylphenyl)-5-(4-hydroxyphenyl) -4,5-dihydro -1 H-pyrazol-1-yl]benzene-1-sulfonamide or 6-chloro-10-(4-ethylphenyl)-4-hydroxypyrimido[4,5-b]quinolin-2(10H)-one, which is a MsrB1 inhibitor, and an anticancer composition comprising same. The MsrB1 inhibitor of the present invention has been confirmed to inhibit differentiation into tumor-friendly M2 macrophages and to suppress tumor growth. In addition, the MsrB1 inhibitor of the present invention was found to exhibit anticancer effects through immune regulation within the tumor microenvironment, and thus can be usefully applied as a composition for cancer treatment.

The present application relates to the field of image recognition, and more particularly to a method and system for predicting and analyzing adrenal metastasis based on image recognition. The method comprises the following steps: collecting patient adrenal PET-CT monitoring images at multiple time points, and performing visual detection of metastasis at each time point, and extracting metastasis bounding boxes at multiple time points; according to the metastasis bounding box, the dynamic fluctuation analysis of the surrounding tissue microenvironment and the boundary immune influence degree evaluation are carried out, and a multi-cycle immune response intensity graph is constructed; the metastasis change trend evolution of the metastasis bounding box is carried out, and the metastasis image change trend graph at different time points is obtained; according to the metastasis bounding box, the surrounding tissue texture feature difference is identified, and the potential tumor metastatic cells are extracted. The present application predicts the future change of metastasis by dynamically predicting the development trend of adrenal metastasis, and provides more intuitive metastasis change at different time points.

The invention relates to an application of an RIPK2 inhibitor GSK2983559 in preparation of a medicine for preventing, treating and / or relieving smoke inhalation type lung injury, and the application focuses on targeted inhibition of a core inflammation signal channel of RIPK2-NF-kappa B, regulation and control of excessive activated natural immune response after smoke inhalation, alleviation of acute inflammation injury of airways and pulmonary alveoli, treatment of the smoke inhalation type lung injury, treatment of the smoke inhalation type lung injury, treatment of the smoke inhalation type lung injury, treatment of the smoke inhalation type lung injury and / or treatment of the smoke inhalation type lung injury. And a novel targeted therapeutic drug is provided for clinically preventing and treating lung injury caused by smoke inhalation.

The present invention relates to the field of feature extraction technology, specifically to a feature extraction method and system for CAR-NK cell data, comprising the following steps: collecting CAR-NK cell samples, performing protein analysis on the CAR-NK cell samples in batches, recording changes in protein expression in each batch of CAR-NK cell samples, and performing quantitative analysis on metabolite samples to obtain metabolite concentration data, and standardizing the concentration data to obtain basic data of the cell samples. In the present invention, by quantitatively analyzing proteins and metabolites in CAR-NK cell samples, the response characteristics of cells under different immune environments can be fully captured, immune response grouping and cluster analysis clarify the impact of the immune environment on cell function, the protein-metabolite interaction network reveals the interaction between molecules inside and outside the cell, and by screening and verifying immune markers, provides an accurate basis for immune function assessment. The quantitative analysis of immune reactivity characteristics can track the immune response process in real time, thereby improving the accuracy and depth of research.

A conjugate obtained by binding a benzodiazepine to an antibody or an antigen-binding fragment thereof having immunological reactivity with MCEMP1 protein, the conjugate being an antibody-drug complex (ADC) having a strong anti-tumor effect and being useful for the treatment and / or prevention of cancer, particularly cancer expressing MCEMP1 protein on the cell surface.

The present invention relates to a medicament for treatment and / or prevention of cancer, comprising an antibody or a fragment thereof having an immunological reactivity with CAPRIN-1 protein, and an HDAC inhibitor together or separately in combination.

To provide chimeric antigen receptors (CARs) that specifically bind to a human Kallikrein-2 (hK2), and immunoresponsive cells comprising such CARs, for the treatment of cancer.SOLUTION: Provided is a chimeric antigen receptor (CAR) comprising: (a) an extracellular domain that specifically binds to a human Kallikrein-2 (hK2) antigen, (b) a transmembrane domain, and (c) an intracellular signaling domain optionally comprising at least one costimulatory domain.SELECTED DRAWING: Figure 1A

Disclosed herein are populations of engineered cells comprising a genetic modification to elicit or enhance an amount of IL- 12 that is secreted by the cells. The population of engineered cells can be a population of engineered immune cells (e.g., myeloid progenitor cells), or a population of engineered stem cells. Pharmaceutical compositions, kits, and devices comprising the populations of engineered cells are also provided. Also provided herein are methods of treating a subject having a tumor or stimulating an immune response against a tumor in a subject, comprising administering a population of engineered cells described herein.

Described herein is the use of nucleic acid barcodes as specific labels for MHC multimers to determine the antigen responsiveness in biological samples. After cellular selection the barcode sequence will be revealed by sequencing. This technology allows for detection of multiple (potentially >1000) different antigen-specific cells in a single sample. The technology can be used for T-cell epitope mapping, immune-recognition discovery, diagnostics tests and measuring immune reactivity after vaccination or immune-related therapies.

The invention provides an immune detection method of an immune checkpoint detection kit, and belongs to the technical field of immune checkpoint detection kits.The immune detection method comprises the steps that an immune reaction system containing immune checkpoint antibodies is prepared, incubation is conducted under the constant temperature condition to form a sandwich type immune complex, and the sandwich type immune complex is obtained; phycoerythrin labeled streptavidin is added for fluorescence labeling, a flow cytometer is adopted for fluorescence signal detection after interference substances are removed through multiple times of cleaning, fluorescence image data are processed through an image partitioning optimization model, image processing parameters are dynamically adjusted through a signal enhancement algorithm function and a gating weight function, and the fluorescence image is obtained. A multi-scale feature extraction network based on a visual converter architecture is adopted to realize accurate processing of a complex fluorescence image, finally correlation analysis and matrix decomposition calculation are performed on fluorescence intensity data, and a detection analysis model is established to output index concentration values of immune checkpoints. The problem that complex fluorescence image data are difficult to process accurately at present is solved.

The presently disclosed subject matter provides for methods and compositions for treating cancer (e.g., breast cancer). It relates to mutant phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-targeted T cell receptors (TCRs) that specifically target a mutant PIK3CA peptide (e.g., a human mutant PIK3CA peptide), and immunoresponsive cells comprising such TCRs. The presently disclosed mutant PIK3CA peptide-specific TCRs have enhanced immune-activating properties, including anti-tumor activity.

Provided herein is a cell macroencapsulation device composed of hydrogel in a 3D conformation that optimizes encapsulated cell viability and function when transplanted into a vascularized tissue space. The hydrogel macroencapsulation device is intended to reduce or eliminate immune response to the cell graft, while allowing exchange of encapsulated cell-secreted products, such as insulin. Also described herein is an injection-mold and fabrication process to generate the hydrogel macroencapsulation devices for use in the clinic.

Provided herein are methods for activating an immune cell in a subject. In some embodiments, the methods comprise passing an immune cell from a subject through an immune modulating chamber comprising a tumor cell, thereby activating the immune cell, and returning the activated immune cell to the subject. In some embodiments, the methods further comprise isolating an immune cell-containing portion of a sample and passing the immune cell-containing portion through the immune modulating chamber. Methods of treating cancer and methods of inducing an immune response against a tumor are also provided herein.

The invention belongs to the technical field of chemistry and medicine, and relates to a natural killer T cell agonist which contains a sulfonamide group or a part of the sulfonamide group and has immunoregulatory activity and application of the natural killer T cell agonist. The agonist is a compound with a structure as shown in a formula (1) or a pharmaceutically acceptable salt thereof. According to the invention, a sulfonamide group is introduced to an acyl chain of alpha GalCer, and the binding force between glycolipid molecules and CD1d is enhanced by forming an additional hydrogen bond. By adopting the design concept, the NKT cell agonist with better immunomodulatory activity is obtained, the synthesis method of the series of compounds is simple and efficient, and the screened novel alpha GalCer analogue has obviously improved immunostimulatory activity compared with the original alpha GalCer, can induce immunoreactions with different biases, and has good immunomodulatory activity. Potential candidate drugs are provided for immunotherapy and immune modulation. # imgabs0 #

The invention discloses a targeted nano-vesicle for stage-specific tissue repair as well as a preparation method and an application method of the targeted nano-vesicle. The nano vesicles are formed by fusing cell membranes of dominant cells at different stages in the tissue repair process in an equal mass manner. And the system can be used for accurately delivering and regulating key cells in different tissue repair stages, so that the synergistic promotion of dynamic remodeling of a regeneration environment and tissue regeneration is promoted. The cell membrane is extracted by adopting a low-temperature buffer solution system, the fused cell membrane is formed after mixed incubation, and then the nano-vesicles are prepared by adopting a mechanical membrane extrusion method, so that the membrane protein function and structural characteristics of the source cell membrane are reserved, the stability in a physiological environment is good, the biological safety is good, and obvious immunoreaction or toxicity cannot be caused. And the method has the advantages of low cost, mild process and easiness in large-scale popularization. Through glucose functional modification, the active recognition and targeting capabilities are further enhanced, the limitation of a traditional static targeting or sequential release system is broken through, and the system has a wide application prospect.

The invention discloses an application of SseB protein in preparation of a vaccine for cross-immunization homologous or heterologous serotype salmonella enteritidis. Animal experiments are used for evaluating the immune protection capability of the salmonella enteritidis SseB protein, and results show that the salmonella enteritidis SseB protein has good immunoreactivity and can remarkably relieve clinical symptoms caused by homologous or heterologous serotype wild strains of salmonella enteritidis. The salmonella enteritidis SseB protein with the cross immune protection effect, provided by the invention, has the potential of developing a salmonella enteritidis subunit vaccine.